US Patent Issued to Praxis Precision Medicines on March 24 for "3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4triazolo[4,3-apyrazine as an ion channel modulator" (Massachusetts, California Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,582,652, issued on March 24, was assigned to Praxis Precision Medicines Inc. (Boston).

"3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4triazolo[4,3-apyrazine as an ion channel modulator" was invented by Michael Kristopher Mathieu Kahlig (Redwood City, Calif.), Marion Wittmann (Medford, Mass.), Zoe A. Hughes (Newton, Mass.) and Bernard Ravina (Newton, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure is generally directed to methods of treating a disease, disorder, or condition, e.g., a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated ...